{"DataElement":{"publicId":"3474986","version":"2","preferredName":"Treatment Assignment COGC Protocol Treatment Assignment Type","preferredDefinition":"the assignment to a specific treatment._COGC Protocol specified dose level assignment types.","longName":"TREATMENT_COGC","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2014059","version":"1","preferredName":"Treatment Assignment","preferredDefinition":"the assignment to a specific treatment.","longName":"TX_ASSIGN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176930","version":"1","preferredName":"Treatment","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"Treatment","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7B00-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177638","version":"1","preferredName":"Assignment","preferredDefinition":"Assignment; an undertaking that you have been assigned to do.","longName":"Assignment","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5185-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B31A7164-D7B7-3AD1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for use for AdEERS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3474974","version":"1","preferredName":"COGC Protocol Treatment Assignment Type","preferredDefinition":"COGC Protocol specified dose level assignment types.","longName":"3474974v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"160","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ADVL1111 Dose Level 3","valueDescription":"240 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","ValueMeaning":{"publicId":"3489439","version":"1","preferredName":"240 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","longName":"3489439","preferredDefinition":"ADVL1111 Dose Level 3. 240 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C2AB-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C2C4-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1111 Dose Level 2","valueDescription":"200 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","ValueMeaning":{"publicId":"3489440","version":"1","preferredName":"200 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","longName":"3489440","preferredDefinition":"ADVL1111 Dose Level 2. 200 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C2CE-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C2E7-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1111 Dose Level 1","valueDescription":"170 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","ValueMeaning":{"publicId":"3489441","version":"1","preferredName":"170 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","longName":"3489441","preferredDefinition":"ADVL1111 Dose Level 1.170 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C2F1-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C30A-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1111 Dose Level -1","valueDescription":"125 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","ValueMeaning":{"publicId":"3489442","version":"1","preferredName":"125 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","longName":"3489442","preferredDefinition":"ADVL1111 Dose Level -1. 125 mg/m^2/dose Tivantinib p.o. BID with food, for 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C314-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C32D-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1212 Part B DL 3","valueDescription":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 280 mg/m2/dose","ValueMeaning":{"publicId":"3474975","version":"1","preferredName":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 280 mg/m2/dose","longName":"3474975","preferredDefinition":"ADVL1212 Part B DL 3. Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 280 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3F6D-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3F86-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part B DL 2","valueDescription":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 215 mg/m2/dose","ValueMeaning":{"publicId":"3474976","version":"1","preferredName":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 215 mg/m2/dose","longName":"3474976","preferredDefinition":"ADVL1212 Part B DL 2. Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 215 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3F90-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3FA9-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part B DL 1","valueDescription":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 165 mg/m2/dose","ValueMeaning":{"publicId":"3474977","version":"1","preferredName":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 165 mg/m2/dose","longName":"3474977","preferredDefinition":"ADVL1212 Part B DL 1. Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 165 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3FB3-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3FCC-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part B DL -1","valueDescription":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 130 mg/m2/dose","ValueMeaning":{"publicId":"3474978","version":"1","preferredName":"Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 130 mg/m2/dose","longName":"3474978","preferredDefinition":"ADVL1212 Part B DL -1. Vincristine - 1.5 mg/m2/dose; Dexrazoxane - 450 mg/m2/dose; Doxorubicin - 45 mg/m2/dose; Crizotinib - 130 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3FD6-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3FEF-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part A DL 3","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 280 mg/m2/dose","ValueMeaning":{"publicId":"3474979","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 280 mg/m2/dose","longName":"3474979","preferredDefinition":"ADVL1212 Part A DL 3. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 280 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3FF9-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-4012-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part A DL 2","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 215 mg/m2/dose","ValueMeaning":{"publicId":"3474980","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 215 mg/m2/dose","longName":"3474980","preferredDefinition":"ADVL1212 Part A DL 2. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 215 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-401C-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-4035-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part A DL 1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 165 mg/m2/dose","ValueMeaning":{"publicId":"3474981","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 165 mg/m2/dose","longName":"3474981","preferredDefinition":"ADVL1212 Part A DL 1. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 165 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-403F-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-4058-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part A DL -1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 130 mg/m2/dose","ValueMeaning":{"publicId":"3474982","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 130 mg/m2/dose","longName":"3474982","preferredDefinition":"ADVL1212 Part A DL-1. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib - 130 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-4062-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-407B-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 5","valueDescription":"Cycle 1, MK-8776  - 60 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 60 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534804","version":"1","preferredName":"Cycle 1, MK-8776  - 60 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 60 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534804","preferredDefinition":"ADVL1214 Part A DL 5: Cycle 1, MK-8776  - 60 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 60 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-21E1-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-21FA-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 4","valueDescription":"Cycle 1, MK-8776  - 50 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 50 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534805","version":"1","preferredName":"Cycle 1, MK-8776  - 50 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 50 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534805","preferredDefinition":"ADVL1214 Part A DL 4: Cycle 1, MK-8776  - 50 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 50 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-2204-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-221D-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 3","valueDescription":"Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, Rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534806","version":"1","preferredName":"Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, Rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534806","preferredDefinition":"ADVL1214 Part A DL 3: Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, Rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 50 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-2227-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-2240-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 2","valueDescription":"Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534807","version":"1","preferredName":"Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534807","preferredDefinition":"ADVL1214 Part A DL 2: Cycle 1, MK-8776  - 35 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 35 mg/m2/dose +  Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-224A-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-2263-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 1","valueDescription":"Cycle 1, MK-8776  - 25 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 25 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534808","version":"1","preferredName":"Cycle 1, MK-8776  - 25 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 25 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534808","preferredDefinition":"ADVL1214 Part A DL 1: Cycle 1, MK-8776  - 25 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 25 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-226D-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-2286-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1214 Part A DL 0","valueDescription":"Cycle 1, MK-8776 15 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 15 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","ValueMeaning":{"publicId":"3534809","version":"1","preferredName":"Cycle 1, MK-8776 15 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 15 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","longName":"3534809","preferredDefinition":"ADVL1214 Part A DL 0: Cycle 1, MK-8776 15 mg/m2/dose on Day 1-5, rest days 6-14; Cycle 2+ MK-8776 15 mg/m2/dose + Irinotecan - 40 mg/m2/dose on Day 1-5, Rest Days 6-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-2290-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-22A9-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1211 Dose Level 3","valueDescription":"55 mg/m^2 XL184 p.o daily for a 28 day cycle","ValueMeaning":{"publicId":"3534810","version":"1","preferredName":"55 mg/m^2 XL184 p.o daily for a 28 day cycle","longName":"3534810","preferredDefinition":"ADVL1211 Dose Level 3: 55 mg/m^2 XL184 p.o daily for a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-22B3-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-22CC-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1211 Dose Level 2","valueDescription":"40 mg/m^2 XL184 p.o daily for a 28 day cycle","ValueMeaning":{"publicId":"3534811","version":"1","preferredName":"40 mg/m^2 XL184 p.o daily for a 28 day cycle","longName":"3534811","preferredDefinition":"ADVL1211 Dose Level 2: 40 mg/m^2 XL184 p.o daily for a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-22D6-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-22EF-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1211 Dose Level 1","valueDescription":"30 mg/m^2 XL184 p.o daily for a 28 day cycle","ValueMeaning":{"publicId":"3534812","version":"1","preferredName":"30 mg/m^2 XL184 p.o daily for a 28 day cycle","longName":"3534812","preferredDefinition":"ADVL1211 Dose Level 1: 30 mg/m^2 XL184 p.o daily for a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-22F9-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-2312-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"ADVL1211 Dose Level -1","valueDescription":"23 mg/m^2 XL184 p.o daily for a 28 day cycle","ValueMeaning":{"publicId":"3534813","version":"1","preferredName":"23 mg/m^2 XL184 p.o daily for a 28 day cycle","longName":"3534813","preferredDefinition":"ADVL1211 Dose Level -1: 23 mg/m^2 XL184 p.o daily for a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59C54F3-231C-3748-E040-BB89AD437FA1","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C59C54F3-2335-3748-E040-BB89AD437FA1","beginDate":"2012-07-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","deletedIndicator":"No"},{"value":"AHOD1221 Dose Level 2","valueDescription":"1.8 mg/kg Brentuximab vedotin (i.v. over 30 min; max 180 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course","ValueMeaning":{"publicId":"3536741","version":"1","preferredName":"1.8 mg/kg Brentuximab vedotin (i.v. over 30 min; max 180 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course","longName":"3536741","preferredDefinition":"AHOD1221 Dose Level 2: 1.8 mg/kg Brentuximab vedotin (i.v. over 30 min; max 180 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C624E9A2-716C-0BD3-E040-BB89AD436712","latestVersionIndicator":"Yes","beginDate":"2012-07-31","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C624E9A2-7185-0BD3-E040-BB89AD436712","beginDate":"2012-07-31","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-31","modifiedBy":"ONEDATA","dateModified":"2012-07-31","deletedIndicator":"No"},{"value":"AHOD1221 Dose Level 1","valueDescription":"1.4 mg/kg Brentuximab vedotin (i.v. over 30 min; max 140 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course.","ValueMeaning":{"publicId":"3536742","version":"1","preferredName":"1.4 mg/kg Brentuximab vedotin (i.v. over 30 min; max 140 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course.","longName":"3536742","preferredDefinition":"AHOD1221 Dose Level 1: 1.4 mg/kg Brentuximab vedotin (i.v. over 30 min; max 140 mg) Day 1; 1000 mg/m2/day Gemcitabine (i.v. over 100 min) Day 1 and 8; for 21 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C624E9A2-718F-0BD3-E040-BB89AD436712","latestVersionIndicator":"Yes","beginDate":"2012-07-31","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C624E9A2-71A8-0BD3-E040-BB89AD436712","beginDate":"2012-07-31","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-31","modifiedBy":"ONEDATA","dateModified":"2012-07-31","deletedIndicator":"No"},{"value":"ADVL1213 Dose Level 4","valueDescription":"16 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 1280 mg.","ValueMeaning":{"publicId":"3479491","version":"1","preferredName":"16 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 1280 mg.","longName":"3479491","preferredDefinition":"ADVL1213 Dose Level 4: 16 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 1280 mg.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-961F-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-9638-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"ONEDATA","dateModified":"2012-06-15","deletedIndicator":"No"},{"value":"ADVL1213 Dose Level 3","valueDescription":"12 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 960 mg.","ValueMeaning":{"publicId":"3479492","version":"1","preferredName":"12 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 960 mg.","longName":"3479492","preferredDefinition":"ADVL1213 Dose Level 3: 12 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 960 mg.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-9642-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-965B-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"ONEDATA","dateModified":"2012-06-15","deletedIndicator":"No"},{"value":"ADVL1213 Dose Level 2","valueDescription":"8 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 640 mg.","ValueMeaning":{"publicId":"3479493","version":"1","preferredName":"8 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 640 mg.","longName":"3479493","preferredDefinition":"ADVL1213 Dose Level 2: 8 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 640 mg.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-9665-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-967E-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"ONEDATA","dateModified":"2012-06-15","deletedIndicator":"No"},{"value":"ADVL1213 Dose Level 1","valueDescription":"4 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 320 mg.","ValueMeaning":{"publicId":"3479494","version":"1","preferredName":"4 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 320 mg.","longName":"3479494","preferredDefinition":"ADVL1213 Dose Level 1: 4 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 320 mg.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-9688-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-96A1-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"ONEDATA","dateModified":"2012-06-15","deletedIndicator":"No"},{"value":"ADVL1213 Dose Level -1","valueDescription":"2 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 160 mg.","ValueMeaning":{"publicId":"3479495","version":"1","preferredName":"2 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 160 mg.","longName":"3479495","preferredDefinition":"ADVL1213 Dose Level -1: 2 mg/kg of MORAb-004 IV on Days 1, 8, 15 and 22 on a 28 day course.  Maximum Dose may not exceed 160 mg.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-96AB-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-96C4-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"ONEDATA","dateModified":"2012-06-15","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level -1","valueDescription":"50 mg/m^2 dose MK-1775 p.o. QOD alternating weeks,plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"3729491","version":"1","preferredName":"50 mg/m^2 dose MK-1775 p.o. QOD alternating weeks,plus XRT, over a 6 week cycle.","longName":"3729491","preferredDefinition":"ADVL1217 Dose Level -1. 50 mg/m^2 dose MK-1775 p.o. QOD alternating weeks,plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0D101B-4A99-EC86-E040-BB89AD43138C","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DB0D101B-4AB2-EC86-E040-BB89AD43138C","beginDate":"2013-01-25","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 1","valueDescription":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating weeks ,plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"3729492","version":"1","preferredName":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating weeks ,plus XRT, over a 6 week cycle.","longName":"3729492","preferredDefinition":"ADVL1217 Dose Level 1. 50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating weeks ,plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0D101B-4ABC-EC86-E040-BB89AD43138C","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DB0D101B-4AD5-EC86-E040-BB89AD43138C","beginDate":"2013-01-25","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 2","valueDescription":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating with weeks of QOD dosing, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"3729493","version":"1","preferredName":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating with weeks of QOD dosing, plus XRT, over a 6 week cycle.","longName":"3729493","preferredDefinition":"ADVL1217 Dose Level 2. 50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri alternating with weeks of QOD dosing, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0D101B-4ADF-EC86-E040-BB89AD43138C","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DB0D101B-4AF8-EC86-E040-BB89AD43138C","beginDate":"2013-01-25","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 3","valueDescription":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"3729494","version":"1","preferredName":"50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","longName":"3729494","preferredDefinition":"ADVL1217 Dose Level 3. 50 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0D101B-4B02-EC86-E040-BB89AD43138C","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DB0D101B-4B1B-EC86-E040-BB89AD43138C","beginDate":"2013-01-25","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 4","valueDescription":"95 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"3729495","version":"1","preferredName":"95 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","longName":"3729495","preferredDefinition":"ADVL1217 Dose Level 4. 95 mg/m^2 dose MK-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0D101B-4B25-EC86-E040-BB89AD43138C","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DB0D101B-4B3D-EC86-E040-BB89AD43138C","beginDate":"2013-01-25","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 5","valueDescription":"Irinotecan 90 mg/m2/dose PO + MK-1775 110 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722251","version":"1","preferredName":"Irinotecan 90 mg/m2/dose PO + MK-1775 110 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722251","preferredDefinition":"ADVL1312 Dose Level 5: Irinotecan 90 mg/m2/dose PO + MK-1775 110 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-4FD4-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-4FED-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 4","valueDescription":"Irinotecan 90 mg/m2/dose PO + MK-1775 85 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722252","version":"1","preferredName":"Irinotecan 90 mg/m2/dose PO + MK-1775 85 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722252","preferredDefinition":"ADVL1312 Dose Level 4: Irinotecan 90 mg/m2/dose PO + MK-1775 85 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-4FF7-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-5010-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 3","valueDescription":"Irinotecan 90 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722253","version":"1","preferredName":"Irinotecan 90 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722253","preferredDefinition":"ADVL1312 Dose Level 3: Irinotecan 90 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-501A-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-5033-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 2","valueDescription":"Irinotecan 70 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722254","version":"1","preferredName":"Irinotecan 70 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722254","preferredDefinition":"ADVL1312 Dose Level 2: Irinotecan 70 mg/m2/dose PO + MK-1775 65 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-503D-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-5056-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 1","valueDescription":"Irinotecan 70 mg/m2/dose PO + MK-1775 50 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722255","version":"1","preferredName":"Irinotecan 70 mg/m2/dose PO + MK-1775 50 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722255","preferredDefinition":"ADVL1312 Dose Level 1: Irinotecan 70 mg/m2/dose PO + MK-1775 50 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-5060-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-5079-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1312 Dose Level 0","valueDescription":"Irinotecan 70 mg/m2/dose PO + MK-1775 40 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","ValueMeaning":{"publicId":"3722256","version":"1","preferredName":"Irinotecan 70 mg/m2/dose PO + MK-1775 40 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","longName":"3722256","preferredDefinition":"ADVL1312 Dose Level 0: Irinotecan 70 mg/m2/dose PO + MK-1775 40 mg/m2/dose PO Days 1 to 5, Rest Days 6 to 21, Cefixime 8 mg/kg PO or Cefpodoxime 5 mg/kg PO BID Days -2 to 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA1AAE89-5083-3229-E040-BB89AD43362A","latestVersionIndicator":"Yes","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA1AAE89-509C-3229-E040-BB89AD43362A","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-11","modifiedBy":"ONEDATA","dateModified":"2013-04-11","deletedIndicator":"No"},{"value":"ADVL1111 Dose Level 3B","valueDescription":"240 mg/m^2/dose Tivantinib powder sprinkled on food BID, for 28 day cycle","ValueMeaning":{"publicId":"3733134","version":"1","preferredName":"240 mg/m^2/dose Tivantinib powder sprinkled on food BID, for 28 day cycle","longName":"3733134","preferredDefinition":"ADVL1111 Dose Level 3B: 240 mg/m^2/dose Tivantinib powder sprinkled on food BID, for 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB4BB0BB-CAFE-ECD2-E040-BB89AD4358BF","latestVersionIndicator":"Yes","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB4BB0BB-CB17-ECD2-E040-BB89AD4358BF","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"ONEDATA","dateModified":"2013-04-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 6","valueDescription":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 55 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","ValueMeaning":{"publicId":"4179153","version":"1","preferredName":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 55 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","longName":"4179153","preferredDefinition":"ADVL1411 Dose Level 6 Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 55 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-531A-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5333-5BF5-E040-BB89AD4357DA","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level -1","valueDescription":"Day 1: 400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 15 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","ValueMeaning":{"publicId":"4179154","version":"1","preferredName":"Day 1: 400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 15 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","longName":"4179154","preferredDefinition":"ADVL1411 Dose Level -1 Day 1: 400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 15 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-533D-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5356-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 1","valueDescription":"Day 1:400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","ValueMeaning":{"publicId":"4179155","version":"1","preferredName":"Day 1:400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","longName":"4179155","preferredDefinition":"ADVL1411 Dose Level 1 Day 1:400 mcg/m2/dose BMN 673 PO QD; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-5360-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5379-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 2","valueDescription":"Day 1:400 mcg/m2/dose BMN 673 PO BID; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","ValueMeaning":{"publicId":"4179156","version":"1","preferredName":"Day 1:400 mcg/m2/dose BMN 673 PO BID; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","longName":"4179156","preferredDefinition":"ADVL1411 Dose Level 2 Day 1:400 mcg/m2/dose BMN 673 PO BID; Days 2-6:400 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 800 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-5383-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-539C-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 3","valueDescription":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","ValueMeaning":{"publicId":"4179157","version":"1","preferredName":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","longName":"4179157","preferredDefinition":"ADVL1411 Dose Level 3 Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 20 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-53A6-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-53BF-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 4","valueDescription":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 30 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","ValueMeaning":{"publicId":"4179158","version":"1","preferredName":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 30 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","longName":"4179158","preferredDefinition":"ADVL1411 Dose Level 4 Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 30 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-53C9-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-53E2-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Dose Level 5","valueDescription":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 40 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","ValueMeaning":{"publicId":"4179159","version":"1","preferredName":"Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 40 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","longName":"4179159","preferredDefinition":"ADVL1411 Dose Level 5 Day 1:600 mcg/m2/dose BMN 673 PO BID; Days 2-6:600 mcg/m2/dose BMN 673 and 40 mg/m2/dose Temozolomide PO; on a 28 day cycle, Max BMN 673 1000 mcg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-53EC-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5405-5BF5-E040-BB89AD4357DA","beginDate":"2013-12-19","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1315 Dose Level 3","valueDescription":"4.2 mg/m2 Axitinib PO BID over a 28 day cycle","ValueMeaning":{"publicId":"4355851","version":"1","preferredName":"4.2 mg/m2 Axitinib PO BID over a 28 day cycle","longName":"4355851","preferredDefinition":"ADVL1315 Dose Level 3. 4.2 mg/m2 Axitinib PO BID over a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB83ADBB-FCE3-A47E-E040-BB89AD433FDB","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB83ADBB-FCFC-A47E-E040-BB89AD433FDB","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1315 Dose Level 2","valueDescription":"3.2 mg/m2 Axitinib PO BID over a 28 day cycle","ValueMeaning":{"publicId":"4355852","version":"1","preferredName":"3.2 mg/m2 Axitinib PO BID over a 28 day cycle","longName":"4355852","preferredDefinition":"ADVL1315 Dose Level 2. 3.2 mg/m2 Axitinib PO BID over a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB83ADBB-FD06-A47E-E040-BB89AD433FDB","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB83ADBB-FD1F-A47E-E040-BB89AD433FDB","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1315 Dose Level 1","valueDescription":"2.4 mg/m2 Axitinib PO BID over a 28 day cycle","ValueMeaning":{"publicId":"4355853","version":"1","preferredName":"2.4 mg/m2 Axitinib PO BID over a 28 day cycle","longName":"4355853","preferredDefinition":"ADVL1315 Dose Level 1. 2.4 mg/m2 Axitinib PO BID over a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB83ADBB-FD29-A47E-E040-BB89AD433FDB","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB83ADBB-FD42-A47E-E040-BB89AD433FDB","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1315 Dose Level -1","valueDescription":"1.8 mg/m2 Axitinib PO BID over a 28 day cycle","ValueMeaning":{"publicId":"4355854","version":"1","preferredName":"1.8 mg/m2 Axitinib PO BID over a 28 day cycle","longName":"4355854","preferredDefinition":"ADVL1315 Dose Level -1. 1.8 mg/m2 Axitinib PO BID over a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB83ADBB-FD4C-A47E-E040-BB89AD433FDB","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB83ADBB-FD65-A47E-E040-BB89AD433FDB","beginDate":"2014-06-10","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1314 Dose Level 4","valueDescription":"2.2 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","ValueMeaning":{"publicId":"4168142","version":"1","preferredName":"2.2 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","longName":"4168142","preferredDefinition":"ADVL1314 Dose Level 4: 2.2 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4DD7-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4DF0-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"ONEDATA","dateModified":"2014-02-20","deletedIndicator":"No"},{"value":"ADVL1314 Dose Level 3","valueDescription":"1.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","ValueMeaning":{"publicId":"4168143","version":"1","preferredName":"1.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","longName":"4168143","preferredDefinition":"ADVL1314 Dose Level 3: 1.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4DFA-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4E13-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"ONEDATA","dateModified":"2014-02-20","deletedIndicator":"No"},{"value":"ADVL1314 Dose Level 2","valueDescription":"1.4 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","ValueMeaning":{"publicId":"4168144","version":"1","preferredName":"1.4 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","longName":"4168144","preferredDefinition":"ADVL1314 Dose Level 2: 1.4 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4E1D-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4E36-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"ONEDATA","dateModified":"2014-02-20","deletedIndicator":"No"},{"value":"ADVL1314 Dose Level 1","valueDescription":"1.1 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","ValueMeaning":{"publicId":"4168145","version":"1","preferredName":"1.1 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","longName":"4168145","preferredDefinition":"ADVL1314 Dose Level 1: 1.1 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4E40-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4E59-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"ONEDATA","dateModified":"2014-02-20","deletedIndicator":"No"},{"value":"ADVL1314 Dose Level -1","valueDescription":"0.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","ValueMeaning":{"publicId":"4168146","version":"1","preferredName":"0.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","longName":"4168146","preferredDefinition":"ADVL1314 Dose Level -1: 0.8 mg/m2  Eribulin mesylate i.v., Days 1 and 8 of a 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4E63-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4E7C-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"ONEDATA","dateModified":"2014-02-20","deletedIndicator":"No"},{"value":"AHOD1221 Part B Treatment","valueDescription":"Brentuximab vedotin + Gemcitabine","ValueMeaning":{"publicId":"4683990","version":"1","preferredName":"Brentuximab vedotin + Gemcitabine","longName":"4683990","preferredDefinition":"Brentuximab vedotin + Gemcitabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0DA6F9CA-674D-761C-E050-BB89AD434926","latestVersionIndicator":"Yes","beginDate":"2015-01-27","endDate":null,"createdBy":"WANGC","dateCreated":"2015-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DA65529-4FDC-DC99-E050-BB89AD430196","beginDate":"2015-01-27","endDate":null,"createdBy":"WANGC","dateCreated":"2015-01-27","modifiedBy":"ONEDATA","dateModified":"2015-01-27","deletedIndicator":"No"},{"value":"ADVL1212 Part C DL 3","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 280 mg/m2/dose","ValueMeaning":{"publicId":"4566633","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 280 mg/m2/dose","longName":"4566633","preferredDefinition":"ADVL1212 Part C DL 3. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 280 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-3673-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-368C-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1212 Part C DL 2","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 215 mg/m2/dose","ValueMeaning":{"publicId":"4566634","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 215 mg/m2/dose","longName":"4566634","preferredDefinition":"ADVL1212 Part C DL 2. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 215 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-3696-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-36AF-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1212 Part C DL 1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 165 mg/m2/dose","ValueMeaning":{"publicId":"4566635","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 165 mg/m2/dose","longName":"4566635","preferredDefinition":"ADVL1212 Part C DL 1. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 165 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-36B9-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-36D2-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1212 Part C DL -1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 130 mg/m2/dose","ValueMeaning":{"publicId":"4566636","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 130 mg/m2/dose","longName":"4566636","preferredDefinition":"ADVL1212 Part C DL -1.  Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Formulated Capsules - 130 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-36DC-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-36F5-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1412 Part C DL 1","valueDescription":"1mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","ValueMeaning":{"publicId":"4657693","version":"1","preferredName":"1mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","longName":"4657693","preferredDefinition":"ADVL1412 Part C Dose Level 1 1mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C16C781-9430-707E-E050-BB89AD432763","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCABE34-0CF2-5C54-E050-BB89AD436A47","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"ADVL1412 Part C DL 2","valueDescription":"3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","ValueMeaning":{"publicId":"4657692","version":"1","preferredName":"3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","longName":"4657692","preferredDefinition":"ADVL1412 Part C Dose Level 2 3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C16C781-940D-707E-E050-BB89AD432763","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCABE34-0D08-5C54-E050-BB89AD436A47","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"ADVL1412 DL -1","valueDescription":"1 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","ValueMeaning":{"publicId":"4657695","version":"1","preferredName":"1 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","longName":"4657695","preferredDefinition":"ADVL1412 Dose Level -1 1 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C16C781-9476-707E-E050-BB89AD432763","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D2E779B-3102-69D3-E050-BB89AD430439","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"ADVL1412 DL 1","valueDescription":"3 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","ValueMeaning":{"publicId":"4657694","version":"1","preferredName":"3 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","longName":"4657694","preferredDefinition":"ADVL1412 Dose Level 1 3 mg/kg of Nivolumab IV infused over 60min, on Days 1 and 15 of a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C16C781-9453-707E-E050-BB89AD432763","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D2E779B-3119-69D3-E050-BB89AD430439","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 3","valueDescription":"60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","ValueMeaning":{"publicId":"4759451","version":"1","preferredName":"60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","longName":"4759451","preferredDefinition":"ADVL1414 DL 3: 60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1224C087-7301-2257-E050-BB89AD43147B","latestVersionIndicator":"Yes","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1224C087-731A-2257-E050-BB89AD43147B","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"ONEDATA","dateModified":"2015-03-25","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 2","valueDescription":"45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","ValueMeaning":{"publicId":"4759452","version":"1","preferredName":"45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","longName":"4759452","preferredDefinition":"ADVL1414 DL 2: 45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1224C087-7324-2257-E050-BB89AD43147B","latestVersionIndicator":"Yes","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1224C087-733D-2257-E050-BB89AD43147B","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"ONEDATA","dateModified":"2015-03-25","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 1","valueDescription":"35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","ValueMeaning":{"publicId":"4759453","version":"1","preferredName":"35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","longName":"4759453","preferredDefinition":"ADVL1414 DL 1: 35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1224C087-7347-2257-E050-BB89AD43147B","latestVersionIndicator":"Yes","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1224C087-7360-2257-E050-BB89AD43147B","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"ONEDATA","dateModified":"2015-03-25","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level -1","valueDescription":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","ValueMeaning":{"publicId":"4759454","version":"1","preferredName":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","longName":"4759454","preferredDefinition":"ADVL1414 DL -1: 20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1224C087-736A-2257-E050-BB89AD43147B","latestVersionIndicator":"Yes","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1224C087-7383-2257-E050-BB89AD43147B","beginDate":"2015-03-25","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-25","modifiedBy":"ONEDATA","dateModified":"2015-03-25","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 3A","valueDescription":"60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","ValueMeaning":{"publicId":"4788360","version":"1","preferredName":"60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","longName":"4788360","preferredDefinition":"ADVL1414 DL 3A: 60 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1366F0F1-470E-BB54-E050-BB89AD43464C","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1366F0F1-4727-BB54-E050-BB89AD43464C","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 2A","valueDescription":"45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","ValueMeaning":{"publicId":"4788361","version":"1","preferredName":"45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","longName":"4788361","preferredDefinition":"ADVL1414 DL 2A: 45 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1366F0F1-4731-BB54-E050-BB89AD43464C","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1366F0F1-474A-BB54-E050-BB89AD43464C","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level 1A","valueDescription":"35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","ValueMeaning":{"publicId":"4788362","version":"1","preferredName":"35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","longName":"4788362","preferredDefinition":"ADVL1414 DL 1A: 35 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1366F0F1-4754-BB54-E050-BB89AD43464C","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1366F0F1-476D-BB54-E050-BB89AD43464C","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","deletedIndicator":"No"},{"value":"ADVL1414 Dose Level -1A","valueDescription":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","ValueMeaning":{"publicId":"4788363","version":"1","preferredName":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","longName":"4788363","preferredDefinition":"ADVL1414 DL -1A: 20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course with required prophylaxis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1366F0F1-4777-BB54-E050-BB89AD43464C","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1366F0F1-4790-BB54-E050-BB89AD43464C","beginDate":"2015-04-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","deletedIndicator":"No"},{"value":"ADVL1416 Dose Level 2","valueDescription":"12 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","ValueMeaning":{"publicId":"4809991","version":"1","preferredName":"12 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","longName":"4809991","preferredDefinition":"ADVL1416 DL 2: 12 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154760AF-7155-4CBE-E050-BB89AD4349A8","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154760AF-716E-4CBE-E050-BB89AD4349A8","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1416 Dose Level 1","valueDescription":"8 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","ValueMeaning":{"publicId":"4809992","version":"1","preferredName":"8 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","longName":"4809992","preferredDefinition":"ADVL1416 DL 1: 8 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154760AF-7178-4CBE-E050-BB89AD4349A8","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154760AF-7191-4CBE-E050-BB89AD4349A8","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1416 Dose Level -1","valueDescription":"6 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","ValueMeaning":{"publicId":"4809993","version":"1","preferredName":"6 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","longName":"4809993","preferredDefinition":"ADVL1416 DL -1: 6 mg/kg of Ramucirumab IV infused over 60 min, on Days 1, 15, and 29 of a 42 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154760AF-719B-4CBE-E050-BB89AD4349A8","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154760AF-71B4-4CBE-E050-BB89AD4349A8","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1212 Part D DL 1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 215 mg/m2/dose","ValueMeaning":{"publicId":"5133358","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 215 mg/m2/dose","longName":"5133358","preferredDefinition":"ADVL1212 Part D DL 1. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 215 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8C9B0A-EA36-4EAD-E050-BB89AD4349EF","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8C9B0A-EA4F-4EAD-E050-BB89AD4349EF","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1212 Part D DL -1","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 165 mg/m2/dose","ValueMeaning":{"publicId":"5133359","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 165 mg/m2/dose","longName":"5133359","preferredDefinition":"ADVL1212 Part D DL -1. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 165 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8C9B0A-EA59-4EAD-E050-BB89AD4349EF","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8C9B0A-EA72-4EAD-E050-BB89AD4349EF","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1414 DL -1A","valueDescription":"20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","ValueMeaning":{"publicId":"5355275","version":"1","preferredName":"20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","longName":"5355275","preferredDefinition":"ADVL1414 DL -1A: 20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382AD169-E3F3-3D8B-E050-BB89AD4305F9","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382AD169-E40C-3D8B-E050-BB89AD4305F9","beginDate":"2016-07-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 3A","valueDescription":"60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","ValueMeaning":{"publicId":"5355293","version":"1","preferredName":"60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","longName":"5355293","preferredDefinition":"ADVL1414 DL 3A: 60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E31B-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E334-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 3","valueDescription":"60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","ValueMeaning":{"publicId":"5355294","version":"1","preferredName":"60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","longName":"5355294","preferredDefinition":"ADVL1414 DL 3: 60 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E33E-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E357-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 2A","valueDescription":"45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","ValueMeaning":{"publicId":"5355295","version":"1","preferredName":"45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","longName":"5355295","preferredDefinition":"ADVL1414 DL 2A: 45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E361-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E37A-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 2","valueDescription":"45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","ValueMeaning":{"publicId":"5355296","version":"1","preferredName":"45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","longName":"5355296","preferredDefinition":"ADVL1414 DL 2: 45 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E384-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E39D-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 1A","valueDescription":"35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","ValueMeaning":{"publicId":"5355297","version":"1","preferredName":"35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","longName":"5355297","preferredDefinition":"ADVL1414 DL 1A: 35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (M/W, T/Th, or W/F) on Weeks 1-3, Week 4 rest, with required prophylaxis,on a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E3A7-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E3C0-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1414 DL 1","valueDescription":"35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","ValueMeaning":{"publicId":"5355298","version":"1","preferredName":"35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","longName":"5355298","preferredDefinition":"ADVL1414 DL 1: 35 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B592B-E3CA-85DA-E050-BB89AD433FA0","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B592B-E3E3-85DA-E050-BB89AD433FA0","beginDate":"2016-07-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"APEC1621SC RESCREEN","valueDescription":"Pediatric MATCH ReScreen","ValueMeaning":{"publicId":"5698239","version":"1","preferredName":"Pediatric MATCH ReScreen","longName":"5698239","preferredDefinition":"APEC1621SC RESCREEN: Pediatric MATCH ReScreen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2AF806-7FA3-2D2F-E053-F662850AC09F","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A2AF806-7FBB-2D2F-E053-F662850AC09F","beginDate":"2017-03-07","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"ONEDATA","dateModified":"2017-03-07","deletedIndicator":"No"},{"value":"APEC1621SC SCREENING","valueDescription":"Pediatric MATCH SCREENING","ValueMeaning":{"publicId":"5698240","version":"1","preferredName":"Pediatric MATCH SCREENING","longName":"5698240","preferredDefinition":"APEC1621SC SCREENING: Pediatric MATCH SCREENING","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2AF806-7FC5-2D2F-E053-F662850AC09F","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A2AF806-7FDD-2D2F-E053-F662850AC09F","beginDate":"2017-03-07","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"ONEDATA","dateModified":"2017-03-07","deletedIndicator":"No"},{"value":"APEC1621 SCREENING","valueDescription":"Pediatric MATCH SCREENING","ValueMeaning":{"publicId":"5361038","version":"1","preferredName":"Pediatric MATCH SCREENING","longName":"5361038","preferredDefinition":"APEC1621 SCREENING: Pediatric MATCH SCREENING","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388D9FA8-0806-2A6B-E050-BB89AD430338","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A2AF806-7FF1-2D2F-E053-F662850AC09F","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"ONEDATA","dateModified":"2017-03-07","deletedIndicator":"No"},{"value":"ADVL1414 DL -1","valueDescription":"20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course","ValueMeaning":{"publicId":"5355278","version":"1","preferredName":"20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course","longName":"5355278","preferredDefinition":"ADVL1414 DL -1: 20 mg/m2 Selinexor p.o. twice weekly on days 1,3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382B156D-18A2-5E2A-E050-BB89AD434F5D","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382B156D-18BB-5E2A-E050-BB89AD434F5D","beginDate":"2016-07-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"ADVL1513 DL 2","valueDescription":"4 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","ValueMeaning":{"publicId":"5341461","version":"1","preferredName":"4 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","longName":"5341461","preferredDefinition":"ADVL1513 DL2: 4 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37619762-AF66-4329-E050-BB89AD4351B1","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37619762-AF7F-4329-E050-BB89AD4351B1","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"ADVL1513 DL 1","valueDescription":"3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","ValueMeaning":{"publicId":"5341462","version":"1","preferredName":"3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","longName":"5341462","preferredDefinition":"ADVL1513 DL 1: 3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37619762-AF89-4329-E050-BB89AD4351B1","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37619762-AFA2-4329-E050-BB89AD4351B1","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"ADVL1513 DL-1","valueDescription":"2.3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","ValueMeaning":{"publicId":"5341463","version":"1","preferredName":"2.3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","longName":"5341463","preferredDefinition":"ADVL1513 DL-1: 2.3 mg/m2 Entinostat p.o. weekly on days 1, 8, 15, 22 schedule of a 28 day course.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37619762-AFAC-4329-E050-BB89AD4351B1","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37619762-AFC5-4329-E050-BB89AD4351B1","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"ADVL1611 DL2","valueDescription":"110 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","ValueMeaning":{"publicId":"5207108","version":"1","preferredName":"110 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","longName":"5207108","preferredDefinition":"ADVL1611 DL2. 110 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F472F56-9E38-2892-E050-BB89AD437FF9","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F472F56-9E51-2892-E050-BB89AD437FF9","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"ONEDATA","dateModified":"2016-03-30","deletedIndicator":"No"},{"value":"ADVL1611 DL1","valueDescription":"85 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","ValueMeaning":{"publicId":"5207109","version":"1","preferredName":"85 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","longName":"5207109","preferredDefinition":"ADVL1611 DL1. 85 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F472F56-9E5B-2892-E050-BB89AD437FF9","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F472F56-9E74-2892-E050-BB89AD437FF9","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"ONEDATA","dateModified":"2016-03-30","deletedIndicator":"No"},{"value":"ADVL1611 DL -1","valueDescription":"65 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","ValueMeaning":{"publicId":"5207110","version":"1","preferredName":"65 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","longName":"5207110","preferredDefinition":"ADVL1611 DL -1. 65 mg/ m2/dose AZD1775 p.o. with FLAG Chemotherapy on days 1-5; plus IT Cytarabine, on a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F472F56-9E7E-2892-E050-BB89AD437FF9","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F472F56-9E97-2892-E050-BB89AD437FF9","beginDate":"2016-03-30","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-03-30","modifiedBy":"ONEDATA","dateModified":"2016-03-30","deletedIndicator":"No"},{"value":"APEC1621 RESCREEN","valueDescription":"Pediatric MATCH ReScreen","ValueMeaning":{"publicId":"5400997","version":"1","preferredName":"Pediatric MATCH ReScreen","longName":"5400997","preferredDefinition":"APEC1621 RESCREEN: Pediatric MATCH ReScreen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39D208B1-463E-EBF6-E050-BB89AD4358B1","latestVersionIndicator":"Yes","beginDate":"2016-08-11","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39D208B1-4657-EBF6-E050-BB89AD4358B1","beginDate":"2016-08-11","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-11","modifiedBy":"ONEDATA","dateModified":"2016-08-11","deletedIndicator":"No"},{"value":"ADVL1412 Part D DL 1","valueDescription":"3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","ValueMeaning":{"publicId":"5482041","version":"1","preferredName":"3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","longName":"5482041","preferredDefinition":"ADVL1412 Part D Dose Level 1 3mg/kg Nivolumab IV; 1mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D314520-8446-0A2C-E053-F662850AD74F","latestVersionIndicator":"Yes","beginDate":"2016-09-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D314520-845E-0A2C-E053-F662850AD74F","beginDate":"2016-09-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-23","modifiedBy":"ONEDATA","dateModified":"2016-09-23","deletedIndicator":"No"},{"value":"ADVL1515 DL4","valueDescription":"150 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","ValueMeaning":{"publicId":"5495686","version":"1","preferredName":"150 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","longName":"5495686","preferredDefinition":"ADVL1515 DL4: 150 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC25AC4-6AE6-670C-E053-F662850ADEA2","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC25AC4-6AFF-670C-E053-F662850ADEA2","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ADVL1515 DL3","valueDescription":"125 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","ValueMeaning":{"publicId":"5495687","version":"1","preferredName":"125 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","longName":"5495687","preferredDefinition":"ADVL1515 DL3: 125 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC25AC4-6B09-670C-E053-F662850ADEA2","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC25AC4-6B22-670C-E053-F662850ADEA2","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ADVL1515 DL2","valueDescription":"100 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","ValueMeaning":{"publicId":"5495688","version":"1","preferredName":"100 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","longName":"5495688","preferredDefinition":"ADVL1515 DL2: 100 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC25AC4-6B2C-670C-E053-F662850ADEA2","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC25AC4-6B45-670C-E053-F662850ADEA2","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ADVL1515 DL1","valueDescription":"80 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","ValueMeaning":{"publicId":"5495689","version":"1","preferredName":"80 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","longName":"5495689","preferredDefinition":"ADVL1515 DL1: 80 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC25AC4-6B4F-670C-E053-F662850ADEA2","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC25AC4-6B68-670C-E053-F662850ADEA2","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ADVL1515 DL -1","valueDescription":"60 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","ValueMeaning":{"publicId":"5495690","version":"1","preferredName":"60 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","longName":"5495690","preferredDefinition":"ADVL1515 DL -1: 60 mg/m2 of LY2606368 IV infused over 60 minutes on Days 1 and 15 of a 28 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC25AC4-6B72-670C-E053-F662850ADEA2","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC25AC4-6B8B-670C-E053-F662850ADEA2","beginDate":"2016-09-30","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ACCL15N1CD Patient","valueDescription":"ACCL15N1CD Patient Enrollment","ValueMeaning":{"publicId":"5495716","version":"1","preferredName":"ACCL15N1CD Patient Enrollment","longName":"5495716","preferredDefinition":"ACCL15N1CD Patient Enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DC3C4FF-575D-3E10-E053-F662850AA14D","latestVersionIndicator":"Yes","beginDate":"2016-09-30","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-09-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3DC3C4FF-5776-3E10-E053-F662850AA14D","beginDate":"2016-09-30","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-09-30","modifiedBy":"ONEDATA","dateModified":"2016-09-30","deletedIndicator":"No"},{"value":"ADVL1212 Part D DL -2","valueDescription":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 130 mg/m2/dose","ValueMeaning":{"publicId":"5606651","version":"1","preferredName":"Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 130 mg/m2/dose","longName":"5606651","preferredDefinition":"ADVL1212 Part D DL -2. Cyclophosphamide - 250 mg/m2/dose; Topotecan - 0.75 mg/m2/dose; Crizotinib Microspheres - 130 mg/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43BA7008-389D-668A-E053-F662850A1232","latestVersionIndicator":"Yes","beginDate":"2016-12-15","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-12-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"43BA7008-38B6-668A-E053-F662850A1232","beginDate":"2016-12-15","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-12-15","modifiedBy":"ONEDATA","dateModified":"2016-12-15","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 7","valueDescription":"200 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"5645712","version":"1","preferredName":"200 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","longName":"5645712","preferredDefinition":"ADVL1217 Dose Level 7: 200 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476E139D-5FD5-3284-E053-F662850AF8B0","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476E139D-5FEE-3284-E053-F662850AF8B0","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 6","valueDescription":"160 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"5645713","version":"1","preferredName":"160 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","longName":"5645713","preferredDefinition":"ADVL1217 Dose Level 6: 160 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476E139D-5FF8-3284-E053-F662850AF8B0","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476E139D-6011-3284-E053-F662850AF8B0","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"ADVL1217 Dose Level 5","valueDescription":"130 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","ValueMeaning":{"publicId":"5645714","version":"1","preferredName":"130 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","longName":"5645714","preferredDefinition":"ADVL1217 Dose Level 5: 130 mg/m^2 dose AZD-1775 p.o. daily Mon-Fri Weeks 1-6, plus XRT, over a 6 week cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476E139D-601B-3284-E053-F662850AF8B0","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476E139D-6034-3284-E053-F662850AF8B0","beginDate":"2017-01-31","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"APEC1621H Dose Level -1","valueDescription":"100 mg/m2 orally twice daily Olaparib over a 28 day course","ValueMeaning":{"publicId":"5874202","version":"1","preferredName":"100 mg/m2 orally twice daily Olaparib over a 28 day course","longName":"5874202","preferredDefinition":"APEC1621H Dose Level -1: 100 mg/m2 orally twice daily Olaparib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"521C3C97-EA20-5AC4-E053-F662850A15FE","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"521C3C97-EA39-5AC4-E053-F662850A15FE","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621C Dose Level 1","valueDescription":"900 mg/m2 orally twice daily Tazemetostat over a 28 day course","ValueMeaning":{"publicId":"5879979","version":"1","preferredName":"900 mg/m2 orally twice daily Tazemetostat over a 28 day course","longName":"5879979","preferredDefinition":"APEC1621C Dose Level 1: 900 mg/m2 orally twice daily Tazemetostat over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527CC03A-450B-4A38-E053-F662850A0360","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527CC03A-4524-4A38-E053-F662850A0360","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621A Dose Level 1","valueDescription":"100 mg/m2 p.o. BID LOXO-101 (larotrectinib) over a 28 day course","ValueMeaning":{"publicId":"5879211","version":"1","preferredName":"100 mg/m2 p.o. BID LOXO-101 (larotrectinib) over a 28 day course","longName":"5879211","preferredDefinition":"APEC1621A Dose Level 1: 100 mg/m2 p.o. BID LOXO-101 (larotrectinib) over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527A5131-C877-58A8-E053-F662850A871D","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527A5131-C890-58A8-E053-F662850A871D","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621E Dose Level 1","valueDescription":"25 mg/m2 orally twice daily Selumetinib (AZD6244 hydrogen sulfate) over a 28 day course","ValueMeaning":{"publicId":"5879190","version":"1","preferredName":"25 mg/m2 orally twice daily Selumetinib (AZD6244 hydrogen sulfate) over a 28 day course","longName":"5879190","preferredDefinition":"APEC1621E Dose Level 1: 25 mg/m2 orally twice daily Selumetinib (AZD6244 hydrogen sulfate) over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527A41BE-8546-5976-E053-F662850AC589","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527A41BE-855F-5976-E053-F662850AC589","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621H Dose Level 1","valueDescription":"135 mg/m2 orally twice daily Olaparib over a 28 day course","ValueMeaning":{"publicId":"5874210","version":"1","preferredName":"135 mg/m2 orally twice daily Olaparib over a 28 day course","longName":"5874210","preferredDefinition":"APEC1621H Dose Level 1: 135 mg/m2 orally twice daily Olaparib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52177A2B-53A9-1D2E-E053-F662850AEFF8","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"52177A2B-53C2-1D2E-E053-F662850AEFF8","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621G Dose Level 1","valueDescription":"550 mg/m2 orally twice daily Vemurafenib over a 28 day course","ValueMeaning":{"publicId":"5880605","version":"1","preferredName":"550 mg/m2 orally twice daily Vemurafenib over a 28 day course","longName":"5880605","preferredDefinition":"APEC1621G Dose Level 1: 550 mg/m2 orally twice daily Vemurafenib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"528388A2-B6BB-6A14-E053-F662850A6A35","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528388A2-B6D4-6A14-E053-F662850A6A35","beginDate":"2017-06-21","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"ADVL1514 DL1","valueDescription":"All cycles: 35 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","ValueMeaning":{"publicId":"5808708","version":"1","preferredName":"All cycles: 35 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","longName":"5808708","preferredDefinition":"ADVL1514 DL1 All cycles: 35 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EC978F3-4EF4-5473-E053-F662850A012C","latestVersionIndicator":"Yes","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EC978F3-4F0C-5473-E053-F662850A012C","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"ADVL1514 DL2","valueDescription":"All cycles: 45 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","ValueMeaning":{"publicId":"5808716","version":"1","preferredName":"All cycles: 45 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","longName":"5808716","preferredDefinition":"ADVL1514 DL2 All cycles: 45 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ECE9AB4-71FE-459A-E053-F662850A94B6","latestVersionIndicator":"Yes","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4ECE9AB4-7217-459A-E053-F662850A94B6","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"ADVL1514 DL -1","valueDescription":"All cycles: 20 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","ValueMeaning":{"publicId":"5810654","version":"1","preferredName":"All cycles: 20 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","longName":"5810654","preferredDefinition":"ADVL1514 DL -1 All cycles: 20 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F0BFCB9-B53B-5F00-E053-F662850A760A","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F0BFCB9-B554-5F00-E053-F662850A760A","beginDate":"2017-05-08","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-08","modifiedBy":"ONEDATA","dateModified":"2017-05-08","deletedIndicator":"No"},{"value":"APEC1621H Dose Level 2","valueDescription":"175 mg/m2 orally twice daily Olaparib over a 28 day course","ValueMeaning":{"publicId":"5874218","version":"1","preferredName":"175 mg/m2 orally twice daily Olaparib over a 28 day course","longName":"5874218","preferredDefinition":"APEC1621H Dose Level 2: 175 mg/m2 orally twice daily Olaparib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"521C5B7F-DB75-60F6-E053-F662850AF7AB","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"521C5B7F-DB8E-60F6-E053-F662850AF7AB","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"ADVL1514 DL3","valueDescription":"All cycles: 55 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","ValueMeaning":{"publicId":"5808724","version":"1","preferredName":"All cycles: 55 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","longName":"5808724","preferredDefinition":"ADVL1514 DL3 All cycles: 55 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ECE9E31-6488-4A40-E053-F662850A8B44","latestVersionIndicator":"Yes","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4ECE9E31-64A1-4A40-E053-F662850A8B44","beginDate":"2017-05-05","endDate":null,"createdBy":"JUAREZED","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"APEC1621D Dose Level 2","valueDescription":"115 mg/m2 orally twice daily LY3023414 over a 28 day course","ValueMeaning":{"publicId":"5880081","version":"1","preferredName":"115 mg/m2 orally twice daily LY3023414 over a 28 day course","longName":"5880081","preferredDefinition":"APEC1621D Dose Level 2: 115 mg/m2 orally twice daily LY3023414 over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527DA442-31D5-62E1-E053-F662850A2941","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527DA442-31EE-62E1-E053-F662850A2941","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Dose Level 1","valueDescription":"80 mg/m2 orally twice daily LY3023414 over a 28 day course","ValueMeaning":{"publicId":"5880082","version":"1","preferredName":"80 mg/m2 orally twice daily LY3023414 over a 28 day course","longName":"5880082","preferredDefinition":"APEC1621D Dose Level 1: 80 mg/m2 orally twice daily LY3023414 over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527DA442-31F8-62E1-E053-F662850A2941","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527DA442-3211-62E1-E053-F662850A2941","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Dose Level -1","valueDescription":"55 mg/m2 orally twice daily LY3023414 over a 28 day course","ValueMeaning":{"publicId":"5880083","version":"1","preferredName":"55 mg/m2 orally twice daily LY3023414 over a 28 day course","longName":"5880083","preferredDefinition":"APEC1621D Dose Level -1: 55 mg/m2 orally twice daily LY3023414 over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527DA442-321B-62E1-E053-F662850A2941","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527DA442-3234-62E1-E053-F662850A2941","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621F Dose Level 1","valueDescription":"130 mg/m2 orally once a day Ensartinib over a 28 day course","ValueMeaning":{"publicId":"5879324","version":"1","preferredName":"130 mg/m2 orally once a day Ensartinib over a 28 day course","longName":"5879324","preferredDefinition":"APEC1621F Dose Level 1: 130 mg/m2 orally once a day Ensartinib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527958BB-7F4E-6EDE-E053-F662850A3B9A","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527958BB-7F67-6EDE-E053-F662850A3B9A","beginDate":"2017-06-21","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"ADVL1615 DL3","valueDescription":"Cycle 1: 25mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","ValueMeaning":{"publicId":"5983920","version":"1","preferredName":"Cycle 1: 25mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","longName":"5983920","preferredDefinition":"ADVL1615 DL3: Cycle 1: 25mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A3032D3-2566-25EB-E053-F662850AA88E","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A3032D3-257F-25EB-E053-F662850AA88E","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"ACCL16N1CD Patient","valueDescription":"ACCL16N1CD Patient Enrollment","ValueMeaning":{"publicId":"5960158","version":"1","preferredName":"ACCL16N1CD Patient Enrollment","longName":"5960158","preferredDefinition":"ACCL16N1CD Patient Enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5878EBDC-F040-0AAB-E053-F662850A9540","latestVersionIndicator":"Yes","beginDate":"2017-09-05","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5878EBDC-F059-0AAB-E053-F662850A9540","beginDate":"2017-09-05","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-09-05","modifiedBy":"ONEDATA","dateModified":"2017-09-05","deletedIndicator":"No"},{"value":"ADVL1615 DL2","valueDescription":"Cycle 1: 20mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","ValueMeaning":{"publicId":"5983912","version":"1","preferredName":"Cycle 1: 20mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","longName":"5983912","preferredDefinition":"ADVL1615 DL2: Cycle 1: 20mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A2F8F7E-104E-71CB-E053-F662850A044C","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A2F8F7E-1067-71CB-E053-F662850A044C","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"ADVL1615 DL1","valueDescription":"Cycle 1: 15mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","ValueMeaning":{"publicId":"5983904","version":"1","preferredName":"Cycle 1: 15mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","longName":"5983904","preferredDefinition":"ADVL1615 DL1: Cycle 1: 15mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A302761-6F38-376F-E053-F662850ABCC6","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A302761-6F51-376F-E053-F662850ABCC6","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"APEC1621C DL 1A","valueDescription":"1200 mg/m2 orally twice daily Tazemetostat over a 28 day course","ValueMeaning":{"publicId":"6001393","version":"1","preferredName":"1200 mg/m2 orally twice daily Tazemetostat over a 28 day course","longName":"6001393","preferredDefinition":"APEC1621C DL 1A: 1200 mg/m2 orally twice daily Tazemetostat over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B47F35C-6454-2B4E-E053-F662850A8A79","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B47F35C-646D-2B4E-E053-F662850A8A79","beginDate":"2017-10-11","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"APEC1621B Dose Level 1","valueDescription":"4.7 mg/m2 orally once daily JNJ-42756493 (erdafitinib) over a 28 day course","ValueMeaning":{"publicId":"6005962","version":"1","preferredName":"4.7 mg/m2 orally once daily JNJ-42756493 (erdafitinib) over a 28 day course","longName":"6005962","preferredDefinition":"APEC1621B Dose Level 1: 4.7 mg/m2 orally once daily JNJ-42756493 (erdafitinib) over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BEF9CE3-6BFE-1369-E053-F662850AB0D8","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BEF9CE3-6C17-1369-E053-F662850AB0D8","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"ONEDATA","dateModified":"2017-10-19","deletedIndicator":"No"},{"value":"ADVL1615 DL -1","valueDescription":"Cycle 1: 10mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","ValueMeaning":{"publicId":"5983896","version":"1","preferredName":"Cycle 1: 10mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","longName":"5983896","preferredDefinition":"ADVL1615 DL -1: Cycle 1: 10mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A2FC616-DEDC-5DFD-E053-F662850AE44B","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A2FC616-DEF5-5DFD-E053-F662850AE44B","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"ADVL1614 Dose Level -1","valueDescription":"10 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","ValueMeaning":{"publicId":"6037387","version":"1","preferredName":"10 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","longName":"6037387","preferredDefinition":"ADVL1614 Dose Level -1: 10 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9E8E93-4D87-756F-E053-F662850A8A20","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9E8E93-4DA0-756F-E053-F662850A8A20","beginDate":"2017-12-05","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"ADVL1614 Dose Level 1","valueDescription":"20 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","ValueMeaning":{"publicId":"6037399","version":"1","preferredName":"20 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","longName":"6037399","preferredDefinition":"ADVL1614 Dose Level 1: 20 mg/kg of VX15/2503 IV infused over 60 min, on Days 1 and 15 of a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9EB0FF-75A7-0245-E053-F662850A01CA","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9EB0FF-75C0-0245-E053-F662850A01CA","beginDate":"2017-12-05","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"APEC1621I Dose Level 1","valueDescription":"Palbociclib 75 mg/m2/dose (max dose 125 mg) PO once daily on Days 1-21 over a 28 day course","ValueMeaning":{"publicId":"6160152","version":"1","preferredName":"Palbociclib 75 mg/m2/dose (max dose 125 mg) PO once daily on Days 1-21 over a 28 day course","longName":"6160152","preferredDefinition":"APEC1621I Dose Level 1: Palbociclib 75 mg/m2/dose (max dose 125 mg) PO once daily on Days 1-21 over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E54A93-1C78-6EA5-E053-F662850A8DB4","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E54A93-1C91-6EA5-E053-F662850A8DB4","beginDate":"2018-04-02","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"ADVL1412 Part E DL 1","valueDescription":"1mg/kg Nivolumab IV; 3mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","ValueMeaning":{"publicId":"6345510","version":"1","preferredName":"1mg/kg Nivolumab IV; 3mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","longName":"6345510","preferredDefinition":"ADVL1412 Part E Dose Level 1 1mg/kg Nivolumab IV; 3mg/kg Ipilimumab IV Day1 of a 21day course, cycles1 to 4; 3mg/kg Nivolumab IV on Days1 and 15 of a 28 day Course, cycles 5 plus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"701D788D-A0C8-3000-E053-F662850A4B1D","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"701D788D-A0E0-3000-E053-F662850A4B1D","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","deletedIndicator":"No"},{"value":"ADVL1712 DL1","valueDescription":"20mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","ValueMeaning":{"publicId":"6361444","version":"1","preferredName":"20mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","longName":"6361444","preferredDefinition":"ADVL1712 DL1: 20mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"714E5184-B198-2AB8-E053-F662850A3186","latestVersionIndicator":"Yes","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"714E5184-B1B1-2AB8-E053-F662850A3186","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","deletedIndicator":"No"},{"value":"ADVL1712 DL -1","valueDescription":"15mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","ValueMeaning":{"publicId":"6361445","version":"1","preferredName":"15mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","longName":"6361445","preferredDefinition":"ADVL1712 DL -1: 15mg/m2 Pevo IV on D1,D3,D5 + IT AraC on D0, Aza IV on D1-D5, Flu + AraC IV on D6-D10 of a 35 day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"714E5184-B1BB-2AB8-E053-F662850A3186","latestVersionIndicator":"Yes","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"714E5184-B1D4-2AB8-E053-F662850A3186","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","deletedIndicator":"No"},{"value":"AINV18P1 DL1","valueDescription":"50 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","ValueMeaning":{"publicId":"6303280","version":"1","preferredName":"50 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","longName":"6303280","preferredDefinition":"AINV18P1 DL1: 50 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF896C6-530E-1DCC-E053-F662850A38A8","latestVersionIndicator":"Yes","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF896C6-5327-1DCC-E053-F662850A38A8","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","deletedIndicator":"No"},{"value":"AINV18P1 DL-1","valueDescription":"35 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","ValueMeaning":{"publicId":"6303281","version":"1","preferredName":"35 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","longName":"6303281","preferredDefinition":"AINV18P1 DL-1: 35 mg/ m2/dose Palbociclib p.o. on Days 1-21, with Reinduction Platform, on a 32 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF896C6-5331-1DCC-E053-F662850A38A8","latestVersionIndicator":"Yes","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF896C6-534A-1DCC-E053-F662850A38A8","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","deletedIndicator":"No"},{"value":"APEC1621J Dose Level 2","valueDescription":"350 mg/m2 orally twice daily Ulixertinib over a 28 day course","ValueMeaning":{"publicId":"6360824","version":"1","preferredName":"350 mg/m2 orally twice daily Ulixertinib over a 28 day course","longName":"6360824","preferredDefinition":"APEC1621J Dose Level 2: 350 mg/m2 orally twice daily Ulixertinib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-29B1-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-29CA-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Dose Level 1","valueDescription":"260 mg/m2 orally twice daily Ulixertinib over a 28 day course","ValueMeaning":{"publicId":"6360825","version":"1","preferredName":"260 mg/m2 orally twice daily Ulixertinib over a 28 day course","longName":"6360825","preferredDefinition":"APEC1621J Dose Level 1: 260 mg/m2 orally twice daily Ulixertinib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-29D4-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-29ED-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Dose Level -1","valueDescription":"175 mg/m2 orally twice daily Ulixertinib over a 28 day course","ValueMeaning":{"publicId":"6360826","version":"1","preferredName":"175 mg/m2 orally twice daily Ulixertinib over a 28 day course","longName":"6360826","preferredDefinition":"APEC1621J Dose Level -1: 175 mg/m2 orally twice daily Ulixertinib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-29F7-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-2A10-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"ADVL1812 DL 2","valueDescription":"ADVL1812 DL 2. 700 ng/kg/day Flotetuzumab","ValueMeaning":{"publicId":"6548681","version":"1","preferredName":"ADVL1812 DL 2. 700 ng/kg/day Flotetuzumab","longName":"6548681","preferredDefinition":"ADVL1812 DL 2. 700 ng/kg/day Flotetuzumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A04AACC-36D0-6D39-E053-F662850AD4A1","latestVersionIndicator":"Yes","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A04AACC-36E9-6D39-E053-F662850AD4A1","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","deletedIndicator":"No"},{"value":"ADVL1812 DL 1","valueDescription":"ADVL1812 DL 1. 500 ng/kg/day Flotetuzumab","ValueMeaning":{"publicId":"6548682","version":"1","preferredName":"ADVL1812 DL 1. 500 ng/kg/day Flotetuzumab","longName":"6548682","preferredDefinition":"ADVL1812 DL 1. 500 ng/kg/day Flotetuzumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A04AACC-36F3-6D39-E053-F662850AD4A1","latestVersionIndicator":"Yes","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A04AACC-370C-6D39-E053-F662850AD4A1","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","deletedIndicator":"No"},{"value":"ADVL1812 DL -1","valueDescription":"ADVL1812 DL -1. 300 ng/kg/day Flotetuzumab","ValueMeaning":{"publicId":"6548683","version":"1","preferredName":"ADVL1812 DL -1. 300 ng/kg/day Flotetuzumab","longName":"6548683","preferredDefinition":"ADVL1812 DL -1. 300 ng/kg/day Flotetuzumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A04AACC-3716-6D39-E053-F662850AD4A1","latestVersionIndicator":"Yes","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A04AACC-372F-6D39-E053-F662850AD4A1","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","deletedIndicator":"No"},{"value":"APEC1621C NONCNS","valueDescription":"520 mg/m2 orally twice daily Tazemetostat over a 28 day course","ValueMeaning":{"publicId":"6719415","version":"1","preferredName":"520 mg/m2 orally twice daily Tazemetostat over a 28 day course","longName":"6719415","preferredDefinition":"APEC1621C NONCNS: 520 mg/m2 orally twice daily Tazemetostat over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873C3C1C-7A20-0741-E053-F662850ADEB7","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"873C3C1C-7A39-0741-E053-F662850ADEB7","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"},{"value":"APEC1621C ENROLL","valueDescription":"APEC1621C Patient Enrollment first step","ValueMeaning":{"publicId":"6719416","version":"1","preferredName":"APEC1621C Patient Enrollment first step","longName":"6719416","preferredDefinition":"APEC1621C ENROLL: APEC1621C Patient Enrollment first step","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873C3C1C-7A43-0741-E053-F662850ADEB7","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"873C3C1C-7A5C-0741-E053-F662850ADEB7","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"},{"value":"ADVL1615 DL4","valueDescription":"Cycle 1: 35mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","ValueMeaning":{"publicId":"7140299","version":"1","preferredName":"Cycle 1: 35mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","longName":"7140299","preferredDefinition":"ADVL1615 DL4: Cycle 1: 35mg/m2 Pevo IV on D1,D8,D10,D12. TEMO po + IRIN IV D8-12, 28 day cycle; Cycle 2+: Pevo IV on D1,D3,D5. TEMO po + IRIN IV D1-5, 21 day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C37D964-8372-67BC-E053-F662850A5144","latestVersionIndicator":"Yes","beginDate":"2020-01-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2020-01-15","modifiedBy":"ONEDATA","dateModified":"2020-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C37D964-838B-67BC-E053-F662850A5144","beginDate":"2020-01-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2020-01-15","modifiedBy":"ONEDATA","dateModified":"2020-01-15","deletedIndicator":"No"},{"value":"ADVL1414 WDL2","valueDescription":"55 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","ValueMeaning":{"publicId":"7140774","version":"1","preferredName":"55 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","longName":"7140774","preferredDefinition":"ADVL1414 WDL2: 55 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C462AAF-97BB-42CC-E053-F662850A2267","latestVersionIndicator":"Yes","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C462AAF-97D4-42CC-E053-F662850A2267","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","deletedIndicator":"No"},{"value":"ADVL1414 WDL1","valueDescription":"45 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","ValueMeaning":{"publicId":"7140775","version":"1","preferredName":"45 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","longName":"7140775","preferredDefinition":"ADVL1414 WDL1: 45 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C462AAF-97DE-42CC-E053-F662850A2267","latestVersionIndicator":"Yes","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C462AAF-97F7-42CC-E053-F662850A2267","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","deletedIndicator":"No"},{"value":"ADVL1414 WDL-1","valueDescription":"35 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","ValueMeaning":{"publicId":"7140776","version":"1","preferredName":"35 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","longName":"7140776","preferredDefinition":"ADVL1414 WDL-1: 35 mg/m2 p.o. Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C462AAF-9801-42CC-E053-F662850A2267","latestVersionIndicator":"Yes","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C462AAF-981A-42CC-E053-F662850A2267","beginDate":"2020-01-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-01-16","modifiedBy":"ONEDATA","dateModified":"2020-01-16","deletedIndicator":"No"},{"value":"PEPN1812 DL -1","valueDescription":"PEPN1812 DL -1 300 nanograms/kg/day Flotetuzumab","ValueMeaning":{"publicId":"7009696","version":"1","preferredName":"PEPN1812 DL -1 300 nanograms/kg/day Flotetuzumab","longName":"7009696","preferredDefinition":"300 nanograms/kg/day Flotetuzumab I.V. infusion target dose starting Day 8 with step up dosing Days 1 to 8  of a 29 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95717182-41BB-0EB2-E053-F662850A36F3","latestVersionIndicator":"Yes","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95717182-41D4-0EB2-E053-F662850A36F3","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","deletedIndicator":"No"},{"value":"ADVL18P1 DL1","valueDescription":"ADVL18P1 DL1: 100 mg Enasidenib p.o. daily on a 28 day course","ValueMeaning":{"publicId":"7113182","version":"1","preferredName":"ADVL18P1 DL1: 100 mg Enasidenib p.o. daily on a 28 day course","longName":"7113182","preferredDefinition":"ADVL18P1 DL1: 100 mg Enasidenib p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A7AE360-B7AE-794D-E053-F662850A70FC","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A7AE360-B7C7-794D-E053-F662850A70FC","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"},{"value":"ADVL18P1 DL1A","valueDescription":"ADVL18P1 DL1A: 50 mg Enasidenib p.o. daily on a 28 day course","ValueMeaning":{"publicId":"7113183","version":"1","preferredName":"ADVL18P1 DL1A: 50 mg Enasidenib p.o. daily on a 28 day course","longName":"7113183","preferredDefinition":"ADVL18P1 DL1A: 50 mg Enasidenib p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A7AE360-B7D1-794D-E053-F662850A70FC","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A7AE360-B7EA-794D-E053-F662850A70FC","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"},{"value":"PEPN1812 DL2","valueDescription":"PEPN1812 DL2 700 nanograms/kg/day Flotetuzumab","ValueMeaning":{"publicId":"7009767","version":"1","preferredName":"PEPN1812 DL2 700 nanograms/kg/day Flotetuzumab","longName":"7009767","preferredDefinition":"700 nanograms/kg/day Flotetuzumab I.V. infusion target dose starting Day 8 with step up dosing Days 1 to 8  of a 29 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95700282-6948-0EB6-E053-F662850A5227","latestVersionIndicator":"Yes","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95700282-6961-0EB6-E053-F662850A5227","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","deletedIndicator":"No"},{"value":"PEPN1812 DL1","valueDescription":"PEPN1812 DL1 500 nanograms/kg/day Flotetuzumab","ValueMeaning":{"publicId":"7009759","version":"1","preferredName":"PEPN1812 DL1 500 nanograms/kg/day Flotetuzumab","longName":"7009759","preferredDefinition":"500 nanograms/kg/day Flotetuzumab I.V. infusion target dose starting Day 8 with step up dosing Days 1 to 7  of a 29 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"956FF73C-E978-0EC3-E053-F662850AEE38","latestVersionIndicator":"Yes","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"956FF73C-E991-0EC3-E053-F662850AEE38","beginDate":"2019-10-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-10-21","modifiedBy":"ONEDATA","dateModified":"2019-10-21","deletedIndicator":"No"},{"value":"ADVL1514 DL -2","valueDescription":"All cycles: 15 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 then once daily through the cycle.","ValueMeaning":{"publicId":"7255248","version":"1","preferredName":"All cycles: 15 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 then once daily through the cycle.","longName":"7255248","preferredDefinition":"ADVL1514 DL -2 All cycles: 15 mg/m2 ABI-009 IV over 30 mins D1 and D8; Cycle 2+: 125mg/m2 TEMO + 90mg/m2 IRIN PO D1-D5 + Cefixime PO D-2 to D8 then once daily through the cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3D293A8-2376-6E25-E053-F662850AD02D","latestVersionIndicator":"Yes","beginDate":"2020-04-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D293A8-238F-6E25-E053-F662850AD02D","beginDate":"2020-04-21","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"APEC1621K Dose Level 1","valueDescription":"290 mg/m2 orally once daily ivosidenib over a 28 day course","ValueMeaning":{"publicId":"7181292","version":"1","preferredName":"290 mg/m2 orally once daily ivosidenib over a 28 day course","longName":"7181292","preferredDefinition":"APEC1621K Dose Level 1: 290 mg/m2 orally once daily ivosidenib over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EF7AD68-F176-4302-E053-F662850A0D69","latestVersionIndicator":"Yes","beginDate":"2020-02-19","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-19","modifiedBy":"ONEDATA","dateModified":"2020-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9EF7AD68-F18F-4302-E053-F662850A0D69","beginDate":"2020-02-19","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-19","modifiedBy":"ONEDATA","dateModified":"2020-02-19","deletedIndicator":"No"},{"value":"APEC1621M Dose Level 1","valueDescription":"Tipifarnib 350 mg/m2/dose orally or via NG- or G- tube twice daily (maximum 600 mg/dose BID) on Days 1-7 and 15-21","ValueMeaning":{"publicId":"7334218","version":"1","preferredName":"Tipifarnib 350 mg/m2/dose orally or via NG- or G- tube twice daily (maximum 600 mg/dose BID) on Days 1-7 and 15-21","longName":"7334218","preferredDefinition":"APEC1621M Dose Level 1: Tipifarnib 350 mg/m2/dose orally or via NG- or G- tube twice daily (maximum 600 mg/dose BID) on Days 1-7 and 15-21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A83D3DA1-17F1-6263-E053-4EBD850AD959","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A83D3DA1-180A-6263-E053-4EBD850AD959","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","deletedIndicator":"No"},{"value":"APEC1621N Dose Level 1","valueDescription":"LOXO-292 dose of 90 mg/m2/dose twice daily (max dose 160 mg BID); a cycle will be 28 days. Evaluations will occur every other cycle x 3, then every third cycle.","ValueMeaning":{"publicId":"7391931","version":"1","preferredName":"LOXO-292 dose of 90 mg/m2/dose twice daily (max dose 160 mg BID); a cycle will be 28 days. Evaluations will occur every other cycle x 3, then every third cycle.","longName":"7391931","preferredDefinition":"APEC1621N Dose Level 1: LOXO-292 dose of 90 mg/m2/dose twice daily (max dose 160 mg BID); a cycle will be 28 days. Evaluations will occur every other cycle x 3, then every third cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACCB6656-677E-56A0-E053-4EBD850A49FD","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACCB6656-6797-56A0-E053-4EBD850A49FD","beginDate":"2020-08-13","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"PEPN1924 Dose Level -2","valueDescription":"DS-8201a 3.2 mg/kg IV infusion every 3 weeks","ValueMeaning":{"publicId":"7490584","version":"1","preferredName":"DS-8201a 3.2 mg/kg IV infusion every 3 weeks","longName":"7490584","preferredDefinition":"PEPN1924 Dose Level -2: DS-8201a 3.2 mg/kg IV infusion every 3 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34C3534-C840-23CE-E053-4EBD850AA8BF","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34C3534-C859-23CE-E053-4EBD850AA8BF","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"PEPN1924 Dose Level -1","valueDescription":"DS-8201a 4.4 mg/kg IV infusion every 3 weeks","ValueMeaning":{"publicId":"7490585","version":"1","preferredName":"DS-8201a 4.4 mg/kg IV infusion every 3 weeks","longName":"7490585","preferredDefinition":"PEPN1924 Dose Level -1: DS-8201a 4.4 mg/kg IV infusion every 3 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34C3534-C863-23CE-E053-4EBD850AA8BF","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34C3534-C87C-23CE-E053-4EBD850AA8BF","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"PEPN1924 Dose Level 1","valueDescription":"DS-8201a 5.4 mg/kg IV infusion every 3 weeks","ValueMeaning":{"publicId":"7490586","version":"1","preferredName":"DS-8201a 5.4 mg/kg IV infusion every 3 weeks","longName":"7490586","preferredDefinition":"PEPN1924 Dose Level 1: DS-8201a 5.4 mg/kg IV infusion every 3 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34C3534-C886-23CE-E053-4EBD850AA8BF","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34C3534-C89F-23CE-E053-4EBD850AA8BF","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"PEPN1924 Screening","valueDescription":"PEPN1924 Screening","ValueMeaning":{"publicId":"7490600","version":"1","preferredName":"PEPN1924 Screening","longName":"7490600","preferredDefinition":"PEPN1924 Screening","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34D2E51-0F63-5001-E053-4EBD850AF9CC","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34D2E51-0F7C-5001-E053-4EBD850AF9CC","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"Dose Level 3:","valueDescription":"Dose Level 3:","ValueMeaning":{"publicId":"7581241","version":"1","preferredName":"Dose Level 3:","longName":"7581241v1.00","preferredDefinition":"650 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA59622-2612-3F9B-E053-4EBD850A367C","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA59622-262B-3F9B-E053-4EBD850A367C","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"Dose Level 2:","valueDescription":"Dose Level 2:","ValueMeaning":{"publicId":"7581242","version":"1","preferredName":"Dose Level 2:","longName":"7581242v1.00","preferredDefinition":"540 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA59622-2635-3F9B-E053-4EBD850A367C","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA59622-264E-3F9B-E053-4EBD850A367C","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"Dose Level 1:","valueDescription":"Dose Level 1:","ValueMeaning":{"publicId":"7581243","version":"1","preferredName":"Dose Level 1:","longName":"7581243v1.00","preferredDefinition":"400 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA59622-2658-3F9B-E053-4EBD850A367C","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA59622-2671-3F9B-E053-4EBD850A367C","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level -1:","valueDescription":"PEPN2111 Dose Level -1:","ValueMeaning":{"publicId":"7581244","version":"1","preferredName":"PEPN2111 Dose Level -1:","longName":"7581244v1.00","preferredDefinition":"300 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA59622-267B-3F9B-E053-4EBD850A367C","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":"2023.3.27 Alt VM added per ticket request CADSR0002218. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA59622-2694-3F9B-E053-4EBD850A367C","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 1:","valueDescription":"PEPN2111 Dose Level 1:","ValueMeaning":{"publicId":"7581253","version":"1","preferredName":"PEPN2111 Dose Level 1:","longName":"7581253v1.00","preferredDefinition":"400 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA5A250-D0E2-4879-E053-4EBD850A387C","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":"2023.3.21 Alt VM added. 2023.3.27 ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA5A250-D0FB-4879-E053-4EBD850A387C","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 2:","valueDescription":"PEPN2111 Dose Level 2:","ValueMeaning":{"publicId":"7581261","version":"1","preferredName":"PEPN2111 Dose Level 2:","longName":"7581261v1.00","preferredDefinition":"540 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA5AA92-6FD4-0BD2-E053-4EBD850A9A3E","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":"2023.3.27 Alt VM added per ticket request CADSR0002218. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA5AA92-6FED-0BD2-E053-4EBD850A9A3E","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2011 Dose Level 3","valueDescription":"8 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","ValueMeaning":{"publicId":"7629246","version":"1","preferredName":"8 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","longName":"7629246","preferredDefinition":"PEPN2011 Dose Level 3: 8 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E9547-AF79-788F-E053-4EBD850A3238","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E9547-AF92-788F-E053-4EBD850A3238","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Dose Level 2","valueDescription":"6.5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","ValueMeaning":{"publicId":"7629247","version":"1","preferredName":"6.5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","longName":"7629247","preferredDefinition":"PEPN2011 Dose Level 2: 6.5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E9547-AF9C-788F-E053-4EBD850A3238","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E9547-AFB5-788F-E053-4EBD850A3238","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Dose Level 1","valueDescription":"5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","ValueMeaning":{"publicId":"7629248","version":"1","preferredName":"5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","longName":"7629248","preferredDefinition":"PEPN2011 Dose Level 1: 5 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E9547-AFBF-788F-E053-4EBD850A3238","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E9547-AFD8-788F-E053-4EBD850A3238","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Dose Level -1","valueDescription":"4 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","ValueMeaning":{"publicId":"7629249","version":"1","preferredName":"4 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","longName":"7629249","preferredDefinition":"PEPN2011 Dose Level -1: 4 mg/kg Tegavivint IV over 4 hours on Days 1, 8 and 15 of a 28 days cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E9547-AFE2-788F-E053-4EBD850A3238","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E9547-AFFB-788F-E053-4EBD850A3238","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 3:","valueDescription":"PEPN2111 Dose Level 3:","ValueMeaning":{"publicId":"7581269","version":"1","preferredName":"PEPN2111 Dose Level 3:","longName":"7581269v1.00","preferredDefinition":"650 mg/m2 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA5ADFB-4D4E-20DE-E053-4EBD850A9F55","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA5ADFB-4D67-20DE-E053-4EBD850A9F55","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 3","valueDescription":"650 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","ValueMeaning":{"publicId":"7717204","version":"1","preferredName":"650 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","longName":"7717204","preferredDefinition":"PEPN2111 Dose Level 3: 650 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FB17-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FB30-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 2","valueDescription":"540 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","ValueMeaning":{"publicId":"7717205","version":"1","preferredName":"540 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","longName":"7717205","preferredDefinition":"PEPN2111 Dose Level 2: 540 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FB3A-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FB53-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level 1","valueDescription":"400 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","ValueMeaning":{"publicId":"7717206","version":"1","preferredName":"400 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","longName":"7717206","preferredDefinition":"PEPN2111 Dose Level 1: 400 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FB5D-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FB76-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Dose Level -1","valueDescription":"300 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","ValueMeaning":{"publicId":"7717207","version":"1","preferredName":"300 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","longName":"7717207","preferredDefinition":"PEPN2111 Dose Level -1: 300 mg/m2 CBL0137 IV on days 1 and 8 of a 21-day cycle.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FB80-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FB99-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2112 Dose Level A","valueDescription":"40 mg BID BAY 1895344 (elimusertib) in a 28-day cycle","ValueMeaning":{"publicId":"7817704","version":"1","preferredName":"40 mg BID BAY 1895344 (elimusertib) in a 28-day cycle","longName":"7817704","preferredDefinition":"PEPN2112 Dose Level A: 40 mg BID BAY 1895344 (elimusertib) in a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0507C9C-EFB7-3038-E053-4EBD850A6E0D","latestVersionIndicator":"Yes","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0507C9C-EFD0-3038-E053-4EBD850A6E0D","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","deletedIndicator":"No"},{"value":"PEPN2112 Dose Level 1","valueDescription":"24 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","ValueMeaning":{"publicId":"7817705","version":"1","preferredName":"24 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","longName":"7817705","preferredDefinition":"PEPN2112 Dose Level 1: 24 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0507C9C-EFDA-3038-E053-4EBD850A6E0D","latestVersionIndicator":"Yes","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0507C9C-EFF3-3038-E053-4EBD850A6E0D","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","deletedIndicator":"No"},{"value":"PEPN2112 Dose Level -1","valueDescription":"18 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","ValueMeaning":{"publicId":"7817706","version":"1","preferredName":"18 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","longName":"7817706","preferredDefinition":"PEPN2112 Dose Level -1: 18 mg/m2/dose BAY 1895344 (elimusertib) in a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0507C9C-EFFD-3038-E053-4EBD850A6E0D","latestVersionIndicator":"Yes","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0507C9C-F016-3038-E053-4EBD850A6E0D","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","deletedIndicator":"No"},{"value":"AREN1721 Arm C (cross-over patient)","valueDescription":"AREN1721 Arm C (cross-over patient)","ValueMeaning":{"publicId":"7975315","version":"1","preferredName":"AREN1721 Arm C (cross-over patient)","longName":"7975315","preferredDefinition":"AREN1721 Arm C (cross-over patient)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D49004-5E38-3501-E053-4EBD850AD094","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2D49004-5E51-3501-E053-4EBD850AD094","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","deletedIndicator":"No"},{"value":"AREN1721 Arm A","valueDescription":"AREN1721 Arm A","ValueMeaning":{"publicId":"7975316","version":"1","preferredName":"AREN1721 Arm A","longName":"7975316","preferredDefinition":"AREN1721 Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D49004-5E5B-3501-E053-4EBD850AD094","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2D49004-5E74-3501-E053-4EBD850AD094","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","deletedIndicator":"No"},{"value":"AREN1721 Arm C crossover patient","valueDescription":"AREN1721 Arm C (cross-over patient)","ValueMeaning":{"publicId":"7975315","version":"1","preferredName":"AREN1721 Arm C (cross-over patient)","longName":"7975315","preferredDefinition":"AREN1721 Arm C (cross-over patient)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D49004-5E38-3501-E053-4EBD850AD094","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D4D93788-8C3E-19BD-E053-4EBD850A3656","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2022-01-05","modifiedBy":"ONEDATA","dateModified":"2022-01-05","deletedIndicator":"No"},{"value":"AREN1721 Arm C cross-over patient","valueDescription":"AREN1721 Arm C (cross-over patient)","ValueMeaning":{"publicId":"7975315","version":"1","preferredName":"AREN1721 Arm C (cross-over patient)","longName":"7975315","preferredDefinition":"AREN1721 Arm C (cross-over patient)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D49004-5E38-3501-E053-4EBD850AD094","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D4CBD4AD-F60C-67B9-E053-4EBD850A1622","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2022-01-04","modifiedBy":"ONEDATA","dateModified":"2022-01-04","deletedIndicator":"No"},{"value":"PEPN2113 Dose Level 2","valueDescription":"Uproleselan (GMI-1271) 20mg/Kg/dose + fludarabine + cytarabine","ValueMeaning":{"publicId":"8177167","version":"1","preferredName":"Uproleselan (GMI-1271) 20mg/Kg/dose + fludarabine + cytarabine","longName":"8177167","preferredDefinition":"PEPN2113 Dose Level 2: Uproleselan (GMI-1271) 20mg/Kg/dose + fludarabine + cytarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD95E675-FBE4-7B2B-E053-4EBD850A0FD1","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD95E675-FBFD-7B2B-E053-4EBD850A0FD1","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","deletedIndicator":"No"},{"value":"PEPN2113 Dose Level 1","valueDescription":"Uproleselan (GMI-1271) 10mg/Kg/dose + fludarabine + cytarabine","ValueMeaning":{"publicId":"8177168","version":"1","preferredName":"Uproleselan (GMI-1271) 10mg/Kg/dose + fludarabine + cytarabine","longName":"8177168","preferredDefinition":"PEPN2113 Dose Level 1: Uproleselan (GMI-1271) 10mg/Kg/dose + fludarabine + cytarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD95E675-FC07-7B2B-E053-4EBD850A0FD1","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD95E675-FC20-7B2B-E053-4EBD850A0FD1","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","deletedIndicator":"No"},{"value":"PEPN2113 Dose Level -1","valueDescription":"Uproleselan (GMI-1271) 5mg/Kg/dose + fludarabine + cytarabine","ValueMeaning":{"publicId":"8177169","version":"1","preferredName":"Uproleselan (GMI-1271) 5mg/Kg/dose + fludarabine + cytarabine","longName":"8177169","preferredDefinition":"PEPN2113 Dose Level -1: Uproleselan (GMI-1271) 5mg/Kg/dose + fludarabine + cytarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD95E675-FC2A-7B2B-E053-4EBD850A0FD1","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD95E675-FC43-7B2B-E053-4EBD850A0FD1","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","deletedIndicator":"No"},{"value":"PEPN2121 Adult Dose","valueDescription":"1200 mg Atezolizumab IV plus 600 mg Tiragolumab IV on Day 1 of a 21-day cycle","ValueMeaning":{"publicId":"8178444","version":"1","preferredName":"PEPN2121 Adult Dose: 1200 mg Atezolizumab IV plus 600 mg Tiragolumab IV on Day 1 of a 21-day cycle","longName":"8178444","preferredDefinition":"PEPN2121 Adult Dose: 1200 mg Atezolizumab IV plus 600 mg Tiragolumab IV on Day 1 of a 21-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDC00151-5955-119B-E053-4EBD850AD643","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDC00151-596E-119B-E053-4EBD850AD643","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Pediatric Dose","valueDescription":"15 mg/kg Atezolizumab IV (maximum dose of 1200 mg) plus weight-banded dose of Tiragolumab IV on Day 1 of a 21-day cycle","ValueMeaning":{"publicId":"8178445","version":"1","preferredName":"PEPN2121 Pediatric Dose: 15 mg/kg Atezolizumab IV (maximum dose of 1200 mg) plus weight-banded dose of Tiragolumab IV on Day 1 of a 21-day cycle","longName":"8178445","preferredDefinition":"PEPN2121 Pediatric Dose: 15 mg/kg Atezolizumab IV (maximum dose of 1200 mg) plus weight-banded dose of Tiragolumab IV on Day 1 of a 21-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDC00151-5978-119B-E053-4EBD850AD643","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDC00151-5991-119B-E053-4EBD850AD643","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Part A Dose","valueDescription":null,"ValueMeaning":{"publicId":"10671796","version":"1","preferredName":"PEPN2121 Part A Dose: Weight-banded dose of Tiragolumab IV on Day 1. Cycle 2+: Additional 15 mg/kg Atezolizumab IV on Day 1 of a 21-day cycle (maximum dose of 1200 mg)","longName":"10671796v1.00","preferredDefinition":"PEPN2121 Part A Dose: Weight-banded dose of Tiragolumab IV on Day 1. Cycle 2+: Additional 15 mg/kg Atezolizumab IV on Day 1 of a 21-day cycle (maximum dose of 1200 mg)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E441C3F1-0E88-160E-E053-731AD00A2706","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E441C3F1-0E8D-160E-E053-731AD00A2706","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"Tiragolumab 300mg Dose","valueDescription":null,"ValueMeaning":{"publicId":"10671797","version":"1","preferredName":"300 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients less than or equal to 15 kg","longName":"10671797v1.00","preferredDefinition":"300 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients less than or equal to 15 kg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E441C3F1-0E89-160E-E053-731AD00A2706","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E441C3F1-0E8E-160E-E053-731AD00A2706","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"Tiragolumab 420mg Dose","valueDescription":null,"ValueMeaning":{"publicId":"10671798","version":"1","preferredName":"420 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than 15 kg to less than or equal to 40 kg","longName":"10671798v1.00","preferredDefinition":"420 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than 15 kg to less than or equal to 40 kg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E441C3F1-0E8A-160E-E053-731AD00A2706","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E441C3F1-0E8F-160E-E053-731AD00A2706","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"Tiragolumab 600mg Dose","valueDescription":null,"ValueMeaning":{"publicId":"10671799","version":"1","preferredName":"600 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than 40 kg","longName":"10671799v1.00","preferredDefinition":"600 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than 40 kg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E441C3F1-0E8B-160E-E053-731AD00A2706","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E441C3F1-0E90-160E-E053-731AD00A2706","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"Tiragolumab Adult Dose","valueDescription":null,"ValueMeaning":{"publicId":"10671800","version":"1","preferredName":"600 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than or equal to 18 years old","longName":"10671800v1.00","preferredDefinition":"600 mg Tiragolumab IV on Day 1 of a 21 day cycle for patients greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E441C3F1-0E8C-160E-E053-731AD00A2706","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E441C3F1-0E91-160E-E053-731AD00A2706","beginDate":"2022-07-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"Non-Protocol VCR","valueDescription":null,"ValueMeaning":{"publicId":"11410241","version":"1","preferredName":"Non-Protocol Prescription Vincristine Therapeutic Procedure","longName":"11410241v1.00","preferredDefinition":"Treatment not specified in a protocol._A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure._A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)_An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Protocol","conceptCode":"C25590","definition":"Treatment not specified in a protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prescription","conceptCode":"C28180","definition":"A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAAE8D00-DAB4-6884-E053-731AD00A08A8","latestVersionIndicator":"Yes","beginDate":"2022-10-10","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-10-10","modifiedBy":"CLOHNES","dateModified":"2022-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAAE8D00-DAB5-6884-E053-731AD00A08A8","beginDate":"2022-10-10","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-10-10","modifiedBy":"CLOHNES","dateModified":"2022-10-10","deletedIndicator":"No"},{"value":"ADVL18P1 20mg","valueDescription":null,"ValueMeaning":{"publicId":"12311299","version":"1","preferredName":"ADVL18P1 20mg: 20 mg Enasidenib sprinkles p.o. daily on a 28 day course","longName":"12311299v1.00","preferredDefinition":"ADVL18P1 20mg: 20 mg Enasidenib sprinkles p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B18-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B1E-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 40mg","valueDescription":null,"ValueMeaning":{"publicId":"12311300","version":"1","preferredName":"ADVL18P1 40mg: 40 mg Enasidenib sprinkles p.o. daily on a 28 day course","longName":"12311300v1.00","preferredDefinition":"ADVL18P1 40mg: 40 mg Enasidenib sprinkles p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B19-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B1F-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 50mg","valueDescription":null,"ValueMeaning":{"publicId":"12311301","version":"1","preferredName":"ADVL18P1 50mg: 50 mg Enasidenib tablets p.o. daily on a 28 day course","longName":"12311301v1.00","preferredDefinition":"ADVL18P1 50mg: 50 mg Enasidenib tablets p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B1A-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B20-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 60mg","valueDescription":null,"ValueMeaning":{"publicId":"12311302","version":"1","preferredName":"ADVL18P1 60mg: 60 mg Enasidenib sprinkles p.o. daily on a 28 day course","longName":"12311302v1.00","preferredDefinition":"ADVL18P1 60mg: 60 mg Enasidenib sprinkles p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B1B-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B21-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 80mg","valueDescription":null,"ValueMeaning":{"publicId":"12311303","version":"1","preferredName":"ADVL18P1 80mg: 80 mg Enasidenib sprinkles p.o. daily on a 28 day course","longName":"12311303v1.00","preferredDefinition":"ADVL18P1 80mg: 80 mg Enasidenib sprinkles p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B1C-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B22-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 100mg","valueDescription":null,"ValueMeaning":{"publicId":"12311304","version":"1","preferredName":"ADVL18P1 100mg: 100 mg Enasidenib tablets p.o. daily on a 28 day course","longName":"12311304v1.00","preferredDefinition":"ADVL18P1 100mg: 100 mg Enasidenib tablets p.o. daily on a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D92EC8-6B1D-58F9-E053-731AD00AF5A0","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D92EC8-6B23-58F9-E053-731AD00AF5A0","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"EAY191-C1 Dose Level -1","valueDescription":null,"ValueMeaning":{"publicId":"13269287","version":"1","preferredName":"EAY191-C1 Dose Level -1: Selumetinib (20 mg/m2/dose) orally twice daily & DAY101 (280 mg/m2/dose) orally once weekly, in a 28-day cycle","longName":"13269287v1.00","preferredDefinition":"EAY191-C1 Dose Level -1: Selumetinib (20 mg/m2/dose) orally twice daily & DAY101 (280 mg/m2/dose) orally once weekly, in a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F80D9305-73CB-7F78-E053-731AD00AD1A4","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F80D9305-73CD-7F78-E053-731AD00AD1A4","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"EAY191-C1 Dose Level 1","valueDescription":null,"ValueMeaning":{"publicId":"13269288","version":"1","preferredName":"EAY191-C1 Dose Level 1: Selumetinib (25 mg/m2/dose) orally twice daily & DAY101 (420 mg/m2/dose) orally once weekly, in a 28-day cycle","longName":"13269288v1.00","preferredDefinition":"EAY191-C1 Dose Level 1: Selumetinib (25 mg/m2/dose) orally twice daily & DAY101 (420 mg/m2/dose) orally once weekly, in a 28-day cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F80D9305-73CC-7F78-E053-731AD00AD1A4","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F80D9305-73CE-7F78-E053-731AD00AD1A4","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"PED-CITN-02 DL-1","valueDescription":null,"ValueMeaning":{"publicId":"14240937","version":"1","preferredName":"3x10^5 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","longName":"14240937v1.00","preferredDefinition":"3x10^5 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F20DD9-5FAC-688F-E063-731AD00A4F9D","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F20DD9-5FB0-688F-E063-731AD00A4F9D","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 DL1","valueDescription":null,"ValueMeaning":{"publicId":"14240938","version":"1","preferredName":"1x10^6 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","longName":"14240938v1.00","preferredDefinition":"1x10^6 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F20DD9-5FAD-688F-E063-731AD00A4F9D","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F20DD9-5FB1-688F-E063-731AD00A4F9D","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 DL2","valueDescription":null,"ValueMeaning":{"publicId":"14240939","version":"1","preferredName":"3x10^6 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","longName":"14240939v1.00","preferredDefinition":"3x10^6 transduced T cells/kg, plus or minus 20 percent, Dose of GD2CART","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F20DD9-5FAE-688F-E063-731AD00A4F9D","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F20DD9-5FB2-688F-E063-731AD00A4F9D","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 DL3","valueDescription":null,"ValueMeaning":{"publicId":"14240940","version":"1","preferredName":"1x10^7 transduced T cells/kg, plus or minus 20 percent, Dose level of GD2CART","longName":"14240940v1.00","preferredDefinition":"1x10^7 transduced T cells/kg, plus or minus 20 percent, Dose level of GD2CART","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F20DD9-5FAF-688F-E063-731AD00A4F9D","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F20DD9-5FB3-688F-E063-731AD00A4F9D","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3F57-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"KUMMEROA","dateModified":"2023-11-06","changeDescription":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":"2023.11.6 Updated VM per ticket request CADSR0003045. ak 2023.8.2 PVs added per ticket request CADSR0002682. ak  2023.3.29 PVs added per ticket request CADSR0002221. ak 2023.1.9 PVs added per ticket request CADSR0001884. ak 10/10/22 added AQT and PV for COG cjl; 7/20/2022: fixed the box symbol in VM definitions.wz","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]}],"AlternateNames":[{"name":"TREATMENT_COGC","type":"USED_BY","context":"CTEP"},{"name":"TREATMENT_COGC","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"ADVL1217 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1217 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1212 Treatment Assignment","type":"Preferred Question Text","description":"ADVL1212 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1211 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1211 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1214 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1214 Treatment Assignment","url":null,"context":"CTEP"},{"name":"AHOD1221 Treatment Assignment","type":"Alternate Question Text","description":"AHOD1221 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1213 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1213 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1111 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1111 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1312 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1312 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1411 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1411 Treatment Assignment","url":null,"context":"CTEP"},{"name":"ADVL1314 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1314 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1315 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1315 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1412 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1412 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1414 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1414 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1416 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1416 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1611 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1611 Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621 Treatment Assignment","type":"Alternate Question Text","description":"APEC1621 Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621A Treatment Assignment","type":"Alternate Question Text","description":"APEC1621A Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621D Treatment Assignment","type":"Alternate Question Text","description":"APEC1621D Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1515 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1515 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1513 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1513 Treatment Assignment","url":null,"context":"COG"},{"name":"ACCL15N1CD Treatment Assignment","type":"Alternate Question Text","description":"ACCL15N1CD Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621SC Treatment Assignment","type":"Alternate Question Text","description":"APEC1621SC Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621C Treatment Assignment","type":"Alternate Question Text","description":"APEC1621C Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621E Treatment Assignment","type":"Alternate Question Text","description":"APEC1621E Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1514 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1514 Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621F Treatment Assignment","type":"Alternate Question Text","description":"APEC1621F Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621H Treatment Assignment","type":"Alternate Question Text","description":"APEC1621H Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1615 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1615 Treatment Assignment","url":null,"context":"COG"},{"name":"ACCL16N1CD Treatment Assignment","type":"Alternate Question Text","description":"ACCL16N1CD Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621G Treatment Assignment","type":"Alternate Question Text","description":"APEC1621G Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1614 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1614 Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621I Treatment Assignment","type":"Alternate Question Text","description":"APEC1621I Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621B Treatment Assignment","type":"Alternate Question Text","description":"APEC1621B Treatment Assignment","url":null,"context":"COG"},{"name":"APEC1621J Treatment Assignment","type":"Alternate Question Text","description":"APEC1621J Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1712 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1712 Treatment Assignment","url":null,"context":"COG"},{"name":"AINV18P1 Treatment Assignment","type":"Alternate Question Text","description":"AINV18P1 Treatment Assignment","url":null,"context":"COG"},{"name":"ADVL1812 Treatment Assignment","type":"Alternate Question Text","description":"ADVL1812 Treatment Assignment","url":null,"context":"COG"},{"name":"PEPN1812 Treatment Assignment:","type":"Alternate Question Text","description":"PEPN1812 Treatment Assignment:","url":null,"context":"COG"},{"name":"ADVL18P1 Treatment","type":"Alternate Question Text","description":"ADVL18P1 Treatment","url":null,"context":"COG"},{"name":"APEC1621K Treatment Assignment","type":"Alternate Question Text","description":"APEC1621K Treatment Assignment:","url":null,"context":"COG"},{"name":"APEC1621M Treatment Assignment","type":"Alternate Question Text","description":"APEC1621M Treatment Assignment:","url":null,"context":"COG"},{"name":"APEC1621N Treatment Assignment:","type":"Alternate Question Text","description":"APEC1621N Treatment Assignment:","url":null,"context":"COG"},{"name":"PEPN1924 Treatment Assignment","type":"Alternate Question Text","description":"PEPN1924 Treatment Assignment","url":null,"context":"COG"},{"name":"PEPN2111 Treatment Assignment:","type":"Alternate Question Text","description":"PEPN2111 Treatment Assignment:","url":null,"context":"COG"},{"name":"PEPN2011 Treatment Assignment","type":"Alternate Question Text","description":"PEPN2011 Treatment Assignment","url":null,"context":"COG"},{"name":"PEPN2112 Treatment Assignment","type":"Alternate Question Text","description":"PEPN2112 Treatment Assignment","url":null,"context":"COG"},{"name":"AREN1721 Treatment Assignment:","type":"Alternate Question Text","description":"AREN1721 Treatment Assignment:","url":null,"context":"COG"},{"name":"PEPN2113 Treatment Assignment","type":"Alternate Question Text","description":"PEPN2113 Treatment Assignment","url":null,"context":"COG"},{"name":"PEPN2121 Treatment Assignment","type":"Alternate Question Text","description":"PEPN2121 Treatment Assignment","url":null,"context":"COG"},{"name":"Tiragolumab Treatment Assignment:","type":"Alternate Question Text","description":"Tiragolumab Treatment Assignment:","url":null,"context":"COG"},{"name":"PEPN22P1 Treatment Assignment:","type":"Alternate Question Text","description":"PEPN22P1 Treatment Assignment:","url":null,"context":"COG"},{"name":"EAY191-C1 Treatment Assignment","type":"Alternate Question Text","description":"EAY191-C1 Treatment Assignment","url":null,"context":"COG"},{"name":"PED-CITN-02 Treatment Assignment:","type":"Alternate Question Text","description":"PED-CITN-02 Treatment Assignment:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D40EE2ED-4EC1-22F8-E040-BB89AD4338F7","latestVersionIndicator":"Yes","beginDate":"2013-01-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-01-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-04","changeDescription":"V2 Short Name Change Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":"2023.8.4 AQT added per ticket request CADSR0002685. ak 2023.3.29 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"}}